The EU medicines regulator on Friday rejected Eli Lilly's Alzheimer's drug, saying the treatment's ability to slow cognitive ...

Berenberg Bank analyst Kerry Holford maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on March 21 and set a price target ...

The trial results are among the pharmaceutical industry's most critical and closely watched of the year, as they bring Eli Lilly's drug one step closer to becoming a new, needle-free alternative ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other top stocks to buy according to Two Sigma Investments. Two Sigma Investments, LP ...

Eli Lilly & Co. is adding Alzheimer’s disease resources to the online platform it launched a year ago to sell obesity, diabetes and migraine medicines. Patients will now be able to use ...

Crunching the data, the news looks relatively worse for Novo Nordisk and relatively better for rivals Eli Lilly and Him & Hers Health. First, Novo Nordisk is expanding its program to sell Wegovy ...

He also recommends avoiding Eli Lilly (LLY), as its tremendous revenue growth is hard to repeat. To watch more expert insights and analysis on the latest market action, check out more Market ...

Eli Lilly's weight loss drug Mounjaro, launched last week in India at a significantly lower price than in the US, may still be out of reach for most Indian patients, doctors treating obesity told ...

Healthcare & Pharmaceuticalscategory· March 21, 2025 Eli Lilly launches weight-loss drug Mounjaro in India, beats Novo Nordisk to major market Eli Lilly launched its blockbuster diabetes and ...